Background: Intraoperative radiotherapy with low-energy X-rays (IOXRT) is an increasingly utilized modality during breast conserving therapy (BCT). However, the molecular mechanisms by which it affects the postoperative microenvironment remain to be fully elucidated. Surgical wound fluid (WF) has been demonstrated to modulate cancer cell behavior; however, its metabolomic composition has not been previously characterized in the context of breast cancer. The objective of this study was to evaluate metabolic alterations in postoperative WF and to determine whether IOXRT induces distinct metabolic signatures compared with mastectomy (AMP).Methods: Postoperative WF was collected from 54 breast cancer patients (38 BCT IOXRT; 16 AMP) at two time points: day 1 (A) and day 5 (B) after surgery. The samples were then subjected to analysis using ¹H NMR spectroscopy, encompassing NOESY, CPMG, and JRES techniques. A total of 114 spectral signals were quantified, and 42 metabolites were identified. Multivariate analyses (PCA, PLS DA, OPLS DA) and Wilcoxon signed rank tests were applied to assess temporal and intergroup differences.Results: A clear metabolic separation between time points A and B was observed in both treatment groups. However, statistical analysis revealed no significant differences between BCT IOXRT and AMP. In BCT IOXRT, on the fifth day, WF exhibited a decline in branched chain amino acids, asparagine, lysine, methionine, and glutamate, concomitant with an increase in lactate and pyruvate. AMP-specific alterations encompassed a decrease in 2-oxoglutarate and hypoxanthine on the first day, along with an increase in glucose and creatinine on the fifth day. A decline in ketone bodies (3-hydroxybutyrate, acetoacetate, acetone) was observed in both groups.Conclusions: Postoperative WF demonstrates dynamic metabolic changes reflecting early wound healing processes and treatment-related effects. IOXRT has been found to be associated with enhanced glycolytic signatures and reduced amino acid levels, suggesting altered metabolic activity in the irradiated tumor bed. The metabolomic profiling of WF has the potential to offer a novel source of biomarkers, which could facilitate the assessment of treatment response and tumor microenvironment characteristics.